Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Clearly, ProSense is gaining significant traction and momentum amongst doctors, and we believe this translates into more system and disposable demand globally |
| As independent user data continues to grow and is shared at medical conference and in journals, this is creating a growing momentum as more and more doctors and patients become aware of ProSense as a minimally invasive option |
| Shad Good, a talented health care sales executive, with solid track records in breast diagnostic and therapeutic devices |
| This gives us the greatest confidence in ProSense and IceCure |
| Of course, we were happy if you would have the FDA approval |
| We had some significant achievement on the regulatory front, including approval for ProSense in Brazil and Canada |
| 13 of the published and ongoing studies are for breast cancer, again offering more confidence in our minimally invasive cryoablation options |
| We added robust and less literature in the De Novo filing request, and this is why we had been expecting a more favorable response from the FDA |
| As our VP of sales for North America, this market represents a significant market opportunity for ProSense and I believe that upon a successful outcome of our trial and regulatory strategy, we will be fully realized as Shad and his team will make a significant contribution towards the acceleration of ProSense cells in the U.S |
| This growing body of data and our focus effective commercialization strategy are leading to a greater ProSense usually globally as evidence in the increased cells of ProSense systems and disposable cryoprobes |
| We tried to have the first indication based on our very good and excellent interim results, but the main goal remained to submit for the study after full five-year follow-up |
| We believe as India adopt more early detection for breast cancer, migrating to a minimally invasive solution like ours will improve the life of women by providing them with an alternative to lumpectomy |
| We believe the independent study data is a major catalyst for ProSense adoption and our marketing team and distribution partners are very active at medical conference, speaking with doctors, answering questions and providing non-financial support to those who are interested in conducting studies |
| Despite the challenges we are facing here in Israel, our entire team remains committed and continue to put our best into bringing ProSense to doctors and patients who are clearly appreciating the benefit as an alternative to open surgery |
| For the nine months ended September 30, 2023, ProSense systems and disposable probe sales increased by 11% to $1.7 million, compared to $1.5 million for the nine months ended September 30, 2022, driven by higher cells in the U.S |
| We thank all our investors for your continued support and confidence in IceCure |
| We believe our efforts to reduce non-revenue generating and clinical efforts cost will lower our monthly cash utilization, ensuring the company can meet its primary goals in 2024 |
| Our cryoablation system was highlighted at several medical conferences, and commercial distribution continues to expand as our ProSense systems and disposable prop cells continue to increase |
| Thank you for your great support |
| And as you can see, we had an increase of 11% in sales of products in this year versus last year |
| While our team and everyone in Israel is personally impacted by the war with Hamas, and why it remains difficult and challenging matter, I want to reiterate that IceCure will laser-focus and we will continue to execute our plan of delivering our life-reserving technology to people around the world for improved healthcare outcomes |
| We saw this as an opportunity to make this minimally invasive cryoblation procedure available to women in the U.S |
| We are materialized mainly the new distribution agreement that we signed like Portugal, which again is extremely important for us to -- for them to help to support them for better penetration |
| And one more thing to elaborate on that is the clear benefit of IceCure versus other companies that are working in cryoablation |
| For example, we are using forward-looking statements in this presentation when we discuss the achievements we expect to accomplish as we continue to advance our growth strategy, our position to make significant commercial advances in key markets, pursue the regulatory approvals in various jurisdictions, including with respect to the appeal we file requesting review of the noble classification ProSense, expansion of political applications for retail results from our clinical trials, potential market adoption, and future sales of IceCure’s minimally invasive cryoablation technology, advancing regulatory commercial strategies, strategic plans, and our belief that we are in position to meet our primary goals in 2024 |
| We will continue to push forward, and as reflected in several key developments that have achieved during the current quarter, we are also experiencing a high-tended level of interest for our ProSense system |
| Thank you, and good day |
| Tlalit will also provide more insight into the impact of the independent study and how it helps our global commercial penetration |
| And we wish you, your company and everyone in Israel, best of luck in Godspeed |
| I will turn the call over now to Tlalit, our Vice President of Business Development and Global Marketing, for further insight on how ProSense is gaining increased recognition globally as an excellent minimally invasive alternative to surgery across multiple indications |
| Statement |
|---|
| And notice that the company's top-level revenue in the third quarter appears to be lower than the first and second quarter |
| The decreasing gross profit and gross margin was attributable to the decreasing revenue recognition from the Terumo Distribution Agreement |
| Yes, the third quarter was a little bit challenging |
| As expected, the lower revenue was due to the end of the revenue recognition from the Exclusive Distribution Rights Agreement with the Terumo Corporation in Japan |
| So we see sales are a little bit slower |
| Net loss reported for the nine months ended September 30, 2023, decreased by 11% to $11.66 million, or $0.26 per share, compared with a net loss of $13.03 million or $0.5 per share for the same period last year |
| Tlalit Bussi Tel-Tzure I can share that, it was overbooked |
| This is the kind of a main issue |
Please consider a small donation if you think this website provides you with relevant information